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Abstract
Background: Multidisciplinary attempts to understand the etiology of breast cancer are expanding
to increasingly include new potential markers of disease risk. Those efforts may have maximal
scientific and practical influence if new findings are placed in context of the well-understood lifestyle
and reproductive risk factors or existing risk prediction models for breast cancer. We therefore
evaluated known risk factors for breast cancer in a cancer screening trial that does not have breast
cancer as a study endpoint but is large enough to provide numerous analytic opportunities for
breast cancer.
Methods: We evaluated risk factors for breast cancer (N = 2085) among 70,575 women who
were randomized in the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial. Using
Poisson regression, we calculated adjusted relative risks [RRs, with 95% confidence intervals (CIs)]
for lifestyle and reproductive factors during an average of 5 years of follow-up from date of
randomization.
Results: As expected, increasing age, nulliparity, positive family history of breast cancer, and use
of menopausal hormone therapy were positively associated with breast cancer. Later age at
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menarche (16 years or older vs. < 12: RR = 0.81, 95% CI, 0.65–1.02) or menopause (55 years or
older vs. < 45: RR = 1.29, 95% CI, 1.03–1.62) were less strongly associated with breast cancer than
was expected. There were weak positive associations between taller height and heavier weight, and
only severe obesity [body mass index (BMI; kg/m2) 35 or more vs. 18.5–24.9: RR = 1.21, 95% CI,
1.02–1.43] was statistically significantly associated with breast cancer.
Conclusion:  The ongoing PLCO trial offers continued opportunities for new breast cancer
investigations, but these analyses suggest that the associations between breast cancer and age at
menarche, age at menopause, and obesity might be changing as the underlying demographics of
these factors change.
Clinical Trials Registration: http://www.clinicaltrials.gov, NCT00002540.
Background
Environment, genes, and lifestyle work together to
increase or decrease the probability of developing female
breast cancer [1]. Events early and late in life consistently
influence breast cancer risk [2], but it remains difficult to
explain why some women develop breast cancer and oth-
ers do not [3]. This complicates prevention, yet some
groups consistently have notably higher risks than other
groups: women whose relatives have breast cancer [4],
who first give birth later in life [5], who use exogenous
hormones for extended durations [6], and who are over-
weight or obese after menopause [7].
Most of these conclusions were drawn from individual
studies conducted in the 1970s through the late 1990s, or
collaborative efforts to quantify risk across many studies
[8-10]. Whereas many early studies were exploratory
(because risk factor associations were less clear) contem-
porary studies can have additional or alternative aims,
such as searching for molecular markers, evaluating risk
among younger women or under-studied racial/ethnic
groups, or testing new and refined risk prediction models.
Expanding the breast cancer literature this way is obvi-
ously necessary, but a logical approach for these studies
would be to determine whether the epidemiology of
breast cancer in newer studies matches or differs from the
published literature to date; because these new foci will
likely be most fruitful if placed within the context of
known risk factors for breast cancer, both to see whether
markers modify those risks or are independently associ-
ated with those risk factors [11]. The Prostate, Lung,
Colorectal, and Ovarian (PLCO) Cancer Screening Trial
[12], although not primarily a breast cancer study,
includes extensive data with which to test and develop
hypotheses about breast cancer etiology. We therefore
analyzed relative risk estimates for etiologic factors linked
to breast cancer using the extensive questionnaire data
from the approximate 75,000 post-menopausal women
in the PLCO study.
Methods
Study population
Prorok et al. [13] previously described the full details of
the PLCO trial, which includes both men and women.
This analysis only includes women. The National Cancer
Institute (NCI) designed this trial to determine whether
routine screening with chest X-ray, flexible sigmoidos-
copy, and cancer antigen 125 (CA-125) plus transvaginal
ultrasound could reduce mortality from lung, colorectal,
and ovarian cancers, respectively (Clinical Trials Registra-
tion: http://www.clinicaltrials.gov, NCT00002540).
Recruitment occurred at ten U.S. screening centers (SCs)
between 1993 and 2001. Women were considered eligible
if they were between ages 55 and 74 and had no previous
diagnosis of lung, colorectal, or ovarian cancer. Women
who were receiving cancer treatment or participating in
another screening or prevention trial were ineligible.
Women who had bilateral oophorectomy or were taking
tamoxifen were originally ineligible but later allowed to
enroll. All participants provided informed consent. Insti-
tutional review boards at the NCI and each screening
center approved the study. Although the current analysis
does not address the PLCO trial's main objectives, the
PLCO trial follows the Consolidated Standards of Report-
ing Trials guidelines [14].
Within-center age- and sex-stratified randomization
assigned women to either a control arm, where they were
asked to follow their usual medical care, or an interven-
tion arm, where they were offered screening at regular
intervals [13]. Participants completed a self-administered
risk factor questionnaire at entry, which queried informa-
tion on demographics, smoking, history of cancer in first-
degree relatives, anthropometry, personal medical and
medication use history, and personal history of cancer
screening tests. Reproductive history covered menarche
and menopause, parity and age at first pregnancy, and
gynecologic surgeries, including hysterectomy, oophorec-
tomy, and tubal ligation. The questionnaire ascertained
age at first use and total duration of use of oral contracep-
tives. For menopausal hormone therapy, the question-BMC Cancer 2009, 9:84 http://www.biomedcentral.com/1471-2407/9/84
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naire asked about ever-use, current use, and duration of
use but did not differentiate estrogen-only formulations
from estrogen plus progestin.
Cancer Ascertainment
Participants received a mailed annual study update (ASU)
around each anniversary of their randomization date. The
ASUs ascertained the type and date of any cancer diag-
nosed in the previous year. Study staff contacted non-
responding participants by mail and telephone. To vali-
date the self-reported cancers, staff retrieved medical
records (for standardized medical record abstraction of
pathology reports), death certificates, data from state can-
cer registries, and information from next-of-kin for
deceased participants.
Of 78,231 enrollees (39,116 in the control arm and
39,115 in the intervention arm), 2085 women were diag-
nosed with breast cancer (including 388 carcinomas in
situ) through May 31, 2003. This included 121 (5.8%)
self-reported (i.e., unconfirmed) and 1964 (94.2%) con-
firmed breast cancers. Except where noted, self-reported
breast cancers from both arms were included as study end-
points for this analysis; incidence did not differ between
arms (data not shown).
Statistical Analysis
Analysis excluded 659 women (353 from the intervention
arm and 306 from the control arm) who never returned
an ASU form (and thus for whom breast cancer status was
unknown) and women who reported a positive (N =
5119) or unknown (N = 1878) personal history of any
cancer before randomization. We considered the 70,575
remaining women at risk for developing breast cancer
from the date they completed their baseline questionnaire
until the first of the following: breast cancer diagnosis,
death, or last ASU.
Follow-up is scheduled for at least 13 years [15]. The
mean follow-up time for all women in this analysis was
4.98 years (range, 0.01 years to 9.33 years). The mean
(SD) ages at entry and exit were 62.9 years (5.4) and 67.9
years (6.1), respectively. The total number of woman-
years of observation was 389,714.
Using Poisson regression in EPICURE software [16], we
generated incidence rates and rate ratios (RRs) via stand-
ard likelihood ratio methods [17]. Age and calendar time
were time-dependent but all other variables were time-
independent. We adjusted all RRs for attained age, calen-
dar time, PLCO screening center, age at menarche, age at
natural menopause, age at first birth and parity, first-
degree family history of breast cancer, benign breast dis-
ease, current height, and menopausal hormone therapy
use. Complete-case analyses produced similar results
(data not shown), so, unless noted, we present analyses
that included all participants. We chose the final adjust-
ment factors by comparing models and then dropping
potential confounders (e.g., education, marital status, and
others) whose presence did not substantially affect the
parameter estimates. The final ratio of events to independ-
ent variables was approximately 20:1. Randomization
produced nearly identical distributions of demographic
and reproductive characteristics between arms, and fur-
ther adjustment for trial arm did not change any results
(data not shown).
Results
Most participants were white but nearly 7,000 (9.7%)
were non-white (Table 1). More than 9,000 women
(13.7%) reported having a mother, sister, or daughter
with a history of breast cancer. More than 5000 women
(7.3%) first gave birth after age 30. One third of the par-
ticipants reported a surgical menopause, approximately
one half used oral contraceptives, and two thirds used
menopausal hormone therapy. Based on BMI from self-
reported height and weight at baseline, one third of the
population was overweight (BMI ≥ 25 kg/m2) and approx-
imately one quarter was obese (BMI ≥ 30 kg/m2) or
severely obese (BMI ≥ 35 kg/m2).
As expected, age-specific breast cancer incidence rates rose
with increasing age (Table 2). Compared with white
women, African-American and Asian/Pacific Islander
women were non-significantly more likely to develop
breast cancer after adjustment for other factors (see table
footnote). Increasing parity and earlier age at first birth
were inversely associated with breast cancer. Later ages at
menarche and natural menopause were inversely and pos-
itively, respectively, associated with breast cancer. Current
menopausal hormone therapy use at baseline, regardless
of duration, significantly increased risk, but the baseline
questionnaire did not query hormone therapy formula-
tion or regimen. Height, weight, and BMI were positively
associated with breast cancer, although weight and BMI
associations emerged only after statistical adjustment and
only a few categories produced statistically significant
associations.
Discussion
Our analysis of postmenopausal breast cancer in the
PLCO study revealed interesting differences from the gen-
erally established epidemiology of breast cancer. Increas-
ing age, parity, family history of breast cancer, and use of
menopausal hormone therapy were all associated with
breast cancer as expected. Associations with other key risk
factors – age at menarche, age at menopause, and obesity
– were slightly different from the previously published lit-
erature. These differences have at least two implications
for ongoing and future research on breast cancer.BMC Cancer 2009, 9:84 http://www.biomedcentral.com/1471-2407/9/84
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First, the magnitude of some risk factor associations may
be changing. Published studies have reported consistent,
linear risk relationships with older ages at menarche (e.g.:
5% decrease in risk per 1-year delay after age 12) and men-
opause (e.g.: 3% increase in risk per 1-year delay age at
menopause)[8,9,18]. In contrast, we observed a fairly uni-
form decreased risk with older ages at menarche and a
non-significant increased risk only in the oldest age-at-
menopause group. The larger numbers of older women in
the PLCO cohort could explain the lower RRs. Alterna-
tively, inaccurate recall, especially among older women
[19], or non-differential misclassification could be a fac-
tor, because our questionnaire collected only categorical
data on these ages.
Body size is positively associated with postmenopausal
breast cancer [20]. In a pooled analysis of cohort studies,
risk increased significantly by 7% per 4-kg/m2  BMI
increase, 7% per 5-cm height increase, and 6% per 10-kg
weight increase [7]. In our analysis, all three factors
increased the relative risks by 20%. Despite the large sam-
ple size, only the RRs for the highest categories were statis-
tically significant; the BMI association was stronger than
the height and weight associations.
We observed a higher RR for breast cancer for the combi-
nation of low parity and later age at first birth, whereas an
earlier meta-analysis reported declining RRs with lower
parity in women whose first birth occurred at older ages
Table 1: Baseline characteristics for 70,575 women in the PLCO 
Cancer Screening Trial Cohort.
Number %
Age at baseline
55–59 24,381 34.6
60–64 21,405 30.3
65–69 15,405 21.8
70–74 9,384 13.3
Race/ethnicity
White 62,425 88.5
African-American 4,063 5.8
Asian/Pacific Islander 2,754 3.9
Other* 1,333 1.9
Education
Less than H.S. 4,598 6.5
Completed H.S. 28,588 40.5
Beyond H.S. 37,215 52.7
Unknown 174 0.3
Marital status
Married or living as married 48,749 69.1
Widowed 9,700 13.7
Divorced or separated 9,616 12.7
Never married/missing 2,510 4.5
Mother or sister with breast cancer
No 57,214 81.1
Yes 9,692 13.7
Unknown 3,669 5.2
Age at menarche
< 12 14,259 20.2
12 – 13 37,816 53.6
14 – 15 15,105 21.4
≥ 16 3,208 4.6
Missing 187 0.3
Years of oral contraceptive use
None 32,170 45.6
< 1 year 10,219 14.5
2 – 3 years 7,636 10.8
4 – 5 years 5,208 7.4
6 – 9 years 6,303 8.9
≥ 10 years 8,830 12.5
Missing 209 0.3
Parity and age at first birth
Nulliparous 6,454 9.1
1–2
< 20 years 2,499 3.5
20–24 years 9,336 13.2
25–29 years 6,629 9.4
30–34 years 2,405 3.4
≥ 35 years 1,021 1.5
3–4
< 20 years 5,721 8.1
20–24 years 16,227 23.0
25–29 years 5,942 8.4
30–34 years 1,020 1.5
≥ 35 years 343 0.5
≥ 5
< 20 years 3,818 5.4
20–24 years 7,162 10.2
25–29 years 1,506 2.1
30–34 years 193 0.3
≥ 35 years 194 0.3
Missing or unknown 105 0.2
Menopause Type
Natural 43,572 61.7
Surgical 23,312 3233.0
Radiation or medications 2,346 3.3
Missing 1345 41.9
Age at Natural Menopause
< 45 years 4,468 6.3
45–49 years 11,175 15.8
50–54 years 22,134 31.4
55+ years 5,709 8.1
Missing 86 0.1
Menopausal hormone therapy use
None 23,262 33.0
Former use 11,435 16.2
Current use, ≤ 5 years 11,546 16.4
Current use, > 5 years 23,712 33.6
Missing 620 0.9
Body Mass Index (BMI; kg/m2)
< 18.5 892 1.3
18.5 – 24.9 27,251 38.6
25 – 29 24,214 34.3
30 – 34.9 11,102 15.7
≥ 35 6,297 8.9
Missing 819 1.2
*Other race/ethnicity includes Hispanic, American Indian, and missing/
unknown.
Table 1: Baseline characteristics for 70,575 women in the PLCO 
Cancer Screening Trial Cohort. (Continued)BMC Cancer 2009, 9:84 http://www.biomedcentral.com/1471-2407/9/84
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Table 2: Number of breast cancers, person-years, rates, and RRs by demographic, reproductive, and anthropometric factors.
Breast Cancers* Woman-Years Crude Rate RR** 95% CI
Attained Age
55–59 274 63,088 434.31 1.00 Ref.
60–64 608 108,640 559.65 1.36 1.18–1.57
65–69 582 104,433 557.30 1.44 1.24–1.67
70–74 434 79,134 548.44 1.48 1.26–1.73
75+ 187 34,419 543.30 1.47 1.21–1.79
Race
White 1,854 345,926 535.95 1.00 Ref.
African-American 89 19,765 450.29 1.05 0.84–1.32
Asian/Pacific Islander 111 17,230 644.23 1.14 0.86–1.51
Other/unknown 31 6,793 456.35 0.92 0.64–1.32
Family history of breast cancer
No 1696 336,410 504.15 1.00 Ref.
Yes 389 53,304 729.78 1.44 1.29–1.60
Number of Live Births
0 240 35,545 675.20 1.00 Ref.
1 160 28,296 565.45 0.70 0.55–0.89
2 524 88,510 592.02 0.76 0.62–0.92
3 526 96,163 546.99 0.75 0.62–0.91
4 331 66,673 496.45 0.72 0.59–0.88
5+ 301 73,888 407.37 0.65 0.53–0.80
Age at First Birth
None 240 35,545 675.20 1.00 Ref.
< 20 267 62,165 429.50 0.68 0.53–0.86
20–24 901 181,709 495.85 0.74 0.59–0.91
25–29 471 80,523 584.93 0.83 0.66–1.03
30–34 148 20,822 710.79 1.03 0.81–1.31
35+ 47 6,894 681.75 1.02 0.74–1.41
Age at Menarche
< 12 years 457 76,987 593.61 1.00 Ref.
12–13 years 1099 209,082 525.63 0.86 0.77–0.97
14–15 years 439 84,595 518.94 0.85 0.74–0.97
≥ 16 years 88 17,874 492.34 0.81 0.65–1.02
Age at Menopause
< 45 years 123 25,254 487.05 1.00 Ref.
45–49 years 340 64,113 530.31 1.07 0.87–1.31
50–54 years 700 126,080 555.20 1.12 0.92–1.35
55+ years 211 32,192 655.44 1.29 1.03–1.62
Surgical menopause 574 122,386 469.01 0.84 0.69–1.02
Radiation/medication 94 12,061 779.37 1.32 1.01–1.74
Menopausal hormone therapy use
Never 571 134,329 425.08 1.00 Ref.
Former 280 64,773 432.28 1.02 0.88–1.18
Current, < 5 years 372 61,931 600.67 1.44 1.26–1.66
Current, ≥ 5 years 847 125,006 677.57 1.67 1.49–1.87
Weight (kg)
< 60 437 82,961 526.75 1.00 Ref.
60 – 64.9 310 59,068 524.82 1.03 0.86–1.19
65 – 69.9 311 56,091 554.46 1.18 0.97–1.30
70 – 74.9 257 49,325 521.03 1.08 0.92–1.26
75 – 79.9 267 47,072 567.22 1.21 1.03–1.42
≥ 80 486 91,892 528.88 1.20 1.04–1.38
Height (m)
< 1.60 527 101,460 519.42 1.00 Ref.
1.60 – 1.64 605 117,236 516.05 1.01 0.89–1.13
1.65 – 1.69 561 102,205 548.90 1.06 0.94–1.20
≥ 1.70 385 66,707 577.15 1.11 0.97–1.27
BMI (kg/m2)
< 18.5 25 5,135 486.85 0.88 0.59–1.32
18.5 – 24.9 848 154,447 549.06 1.00 Ref.BMC Cancer 2009, 9:84 http://www.biomedcentral.com/1471-2407/9/84
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[21]. Both that and our study included few multiparous
women who first gave birth after age 35.
These changes could reflect underlying demographic
changes. Mean age of menarche among U.S. females has
declined in recent decades, whereas later age at natural
menopause is more common than before [22,23]. The
prevalence of women who first give birth after age 35 is
increasing, as is the prevalence of obesity [24]. These fac-
tors are potentially related: obesity might spark early
estrogen production and the onset of puberty, whereas
parity and BMI are also associated with later age at meno-
pause [25-28]. Teasing apart the quantitative effect of
these changes on risk factor associations, as well as the
underlying biologic implications, may prove to be a chal-
lenge.
Changing distributions of risk factors will affect the use of
risk prediction models that project individual probabili-
ties of breast cancer and influence eligibility for clinical
trials. The widely used Gail model [29] relies on readily
available medical information, such as age at first birth
and age at menopause. Modified prediction models incor-
porate additional clinical information, such as breast den-
sity [30]. If the relative risk measures that underlie the
projection of absolute risks in these models are changing,
then there is the potential for the models to lose some of
their current calibratory and discriminatory ability. Con-
tinued assessment of model performance among newer
population-based studies with diverse populations could
address this and shed further light on the potential influ-
ence of changing demographics on the epidemiology of
postmenopausal breast cancer.
The known risk factors for breast cancer account for per-
haps only 50% of the population burden of breast cancer
[31]. A polygenic model of breast cancer hypothesizes that
many genetic factors contribute individually small but
collectively large effects that could explain the remaining
50% of the population attributable risk [32]. Based on
extensive results to date of candidate pathways, the overall
effect of low-penetrance SNPs is minimal [33]. The SNP-
based associations that have emerged from marker-based
scans have unknown function or functions unrelated to
the hormonal pathways linked with breast cancer [34,35].
Other important genetic markers with relevant functions
might surface. Exploration of genetic factors is likely to be
most fruitful if placed within the context of the known
risk factors for breast cancer, both to see whether markers
modify those risks or are independently associated with
those risk factors [11].
Whether known or future genetic markers can improve
the performance of existing risk prediction models – or
potential new models that incorporate the clinical hetero-
geneity of breast cancers [36]-is uncertain. Readily availa-
ble lifestyle or questionnaire-based information, such as
reproductive history, will remain the cornerstone of risk
prediction and stratification even if it becomes easy, inex-
pensive, and risk-free for large numbers of women to
determine their genetic profile because the small-magni-
tude risk associations are unlikely to be useful for predic-
tion [37,38]. Changes in the underlying associations
between those risk factors and breast cancer would not
adversely affect such evaluation, but it would require con-
tinued surveillance of breast cancer epidemiology among
contemporary populations, such as PLCO, both individu-
ally and within large-scale replication efforts [32].
Our large sample size makes it unlikely that the deviations
from expectation that we observed were due to chance.
Overall exposure and endpoint data were likely good, but
residual confounding might exist. The questionnaire
lacked information on some risk factors, such as breast-
feeding [8], physical activity [39], and alcohol use [40].
For others – particularly menopausal hormone therapy
[41] – the baseline questionnaire did not allow us to dif-
ferentiate the higher-risk estrogen-plus-progestin formu-
lations from estrogen-only formulations. Compared with
2001 U.S. Census Bureau data on women aged 55–74
[42], lower percentages of PLCO participants reported
receiving some formal education beyond high school
across all racial/ethnic groups: 58% vs. 53% for whites,
67% vs. 52% for African-Americans, and 57% vs. 52% for
Asian/Pacific Islanders. We cannot rule out that other
unmeasured factors may make our study population
25 – 29 712 133,799 532.14 1.06 0.95–1.17
30 – 34.9 305 59,109 516.00 1.10 0.97–1.26
≥ 35 173 32,478 532.67 1.21 1.02–1.43
* Includes confirmed invasive cancers, confirmed in situ lesions, and self-reported cancers.
** Adjusted for attained age, screening center, age at menarche, age at menopause, family history of breast cancer, benign breast disease, height, and 
menopausal hormone therapy (all in categories as shown in the table), plus combined age at first birth and parity (nulliparous or first birth after 35 
years, first birth before age 25, first birth 25–34 years, or unknown) and calendar time (5/31/1993 – 5/31/1995, 6/1/1995 – 5/31/1997, 6/1/1997 – 5/
31/1999, 6/1/1999 – 5/31/2001, and 6/1/2001 – 5/31/2003). RRs for age at first birth and parity were adjusted for the other factor.
Not shown are unknown parity (3 breast cancers and 638 person-years), age at first birth (11 breast cancers and 2,635 person-years), age at 
menarche (2 breast cancers and 1,177 person-years), age at or type of menopause (43 breast cancers and 7,628 person-years), menopausal 
hormone therapy use (15 breast cancers and 3,676 person-years), weight (17 breast cancers and 3,304 person-years), height (7 breast cancers and 
2,107 person-years), and BMI (22 breast cancers and 4,747 person-years).
Table 2: Number of breast cancers, person-years, rates, and RRs by demographic, reproductive, and anthropometric factors. (Continued)BMC Cancer 2009, 9:84 http://www.biomedcentral.com/1471-2407/9/84
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slightly different from the U.S. population on the whole.
Our analysis covered a relatively short follow-up, and con-
tinued follow-up of the PLCO population may confirm
both the validity and generalizability of our findings.
Conclusion
In conclusion, this study of over 75,000 post-menopausal
women suggests that population-level and demographic
changes might influence the magnitude of well-estab-
lished associations between certain recognized risk factors
and breast cancer. These potential changes may become
increasingly important as new molecular epidemiologic
efforts attempt to expand upon existing methods for
understanding relative and absolute risks for breast can-
cer.
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